BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy
Vasiliki Panou(University of Southern Denmark), Oluf Dimitri Røe(Norwegian University of Science and Technology), Weronika Maria Szejniuk(Aalborg University Hospital), Johnni Hansen(Centre international de recherche sur le cancer), Louise Lynggård Andersen, Mogens Vyberg(Aalborg University Hospital), Jenette Creaney(Asbestos Diseases Research Institute), Christos Meristoudis(Aalborg University Hospital), Siaw Ming Chai(Universidad Peruana Cayetano Heredia), Azadeh Birbaneh Asghari(Aalborg University Hospital), Amber Louw(Edith Cowan University)
Cited by 1
Related Papers
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
|Cancer Discovery|2018|630
Painting, firefighting, and shiftwork
|Unknown|2010|257
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
|Journal of Clinical Oncology|2018|229
Shortlasting, Unilateral Neuralgiform Headache Attacks with Conjunctival Injection, Tearing, Sweating, and Rhinorrhea
|Cephalalgia|1989|226
Carcinogenicity of occupational exposure as a firefighter
|The Lancet Oncology|2022|223